Evolus to Participate in the H.C. Wainwright Global Investment Conference

Rhea-AI Summary

Evolus, a performance beauty company, announced participation in the H.C. Wainwright Global Investment Conference on May 24, 2022, from 9:00-9:30 am ET. The event aims to showcase Evolus's cutting-edge products, particularly Jeuveau^®, a neurotoxin dedicated to aesthetics and FDA-approved in 2019. An audio webcast will be available on their website, with a replay for 90 days post-event. Evolus is committed to customer-centric innovation in the aesthetic market.

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in the H.C. Wainwright Global Investment Conference.

Event:	H.C. Wainwright Global Investment Conference
Date:	Tuesday, May 24, 2022
Time:	9:00-9:30 am ET

An audio webcast of this event will be available on the investor relations section of Evolus’ website at www.evolus.com. A replay of the webcast will be available for 90 days after the date of the presentation.

About Evolus, Inc.

Evolus (Nasdaq: EOLS) is a performance beauty company with a customer-centric approach to delivering breakthrough products. Approved in 2019 by the U.S. Food and Drug Administration, Jeuveau^® (prabotulinumtoxinA-xvfs) is the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau^® is powered by Evolus’ unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at www.evolus.com and follow us on LinkedIn, Twitter, Instagram or Facebook.

Jeuveau^® is a registered trademark of Evolus, Inc.

Hi-Pure^™ is a trademark of Daewoong Pharmaceutical Co, Ltd.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220511005100/en/

Investor/Media Contact:

David K. Erickson, Evolus, Inc.

Vice President, Investor Relations

Tel: 949-966-1798

Email: david.erickson@evolus.com

Source: Evolus

FAQ

What is the date of the H.C. Wainwright Global Investment Conference for Evolus?

The conference is scheduled for May 24, 2022.

What time will Evolus present at the H.C. Wainwright Global Investment Conference?

Evolus's presentation is set for 9:00-9:30 am ET.

How can I listen to the Evolus presentation at the conference?

The presentation will be available via an audio webcast on Evolus's website.

What is Jeuveau and its significance for Evolus?

Jeuveau is a neurotoxin dedicated exclusively to aesthetics, approved by the FDA in 2019.

Where can I find more information about Evolus?

Additional details can be found on Evolus's official website, www.evolus.com.